Abstract
References
Articles referenced by this article (95)
Davis, K. L. & Samuels, S. C. in Pharmacological Management of Neurological and Psychiatric Disorders (eds Enna, S. J. & Coyle, J. T.) 267–316 (McGraw–Hill, New York, 1998).
Doody, R. S. Therapeutic standards in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 13 (Suppl. 2), S20–S26 (1999).
Evaluation of memantine for the treatment of Alzheimer's disease.
Expert Opin Pharmacother, (12):2305-2313 2003
MED: 14640929
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.
Science, (5580):353-356 2002
MED: 12130773
Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.
Nature, (6880):535-539 2002
MED: 11932745
Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss.
Proc Natl Acad Sci U S A, (18):10417-10422 2003
MED: 12925731
Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.
Neuron, (3):665-676 2001
MED: 11430801
Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.
Arch Neurol, (12):1685-1691 2003
MED: 14676042
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.
Nature, (6740):173-177 1999
MED: 10408445
Show 10 more references (10 of 95)
Citations & impact
Impact metrics
Article citations
Nanomaterials that Aid in the Diagnosis and Treatment of Alzheimer's Disease, Resolving Blood-Brain Barrier Crossing Ability.
Adv Sci (Weinh), 11(38):e2403473, 05 Aug 2024
Cited by: 1 article | PMID: 39101248 | PMCID: PMC11481234
Review Free full text in Europe PMC
Discovery of a novel pyrido[1,2-a]thiazolo[5,4-d]pyrimidinone derivatives with excellent potency against acetylcholinesterase.
Mol Divers, 27 Jun 2024
Cited by: 0 articles | PMID: 38935303
Alzheimer's disease: In silico study of rosemary diterpenes activities.
Curr Res Toxicol, 6:100159, 29 Feb 2024
Cited by: 0 articles | PMID: 38455759 | PMCID: PMC10918482
Upregulation of endocytic protein expression in the Alzheimer's disease male human brain.
Aging Brain, 4:100084, 21 Jun 2023
Cited by: 4 articles | PMID: 37449017 | PMCID: PMC10336166
Improving the Treatment Effect of Carotenoids on Alzheimer's Disease through Various Nano-Delivery Systems.
Int J Mol Sci, 24(8):7652, 21 Apr 2023
Cited by: 4 articles | PMID: 37108814 | PMCID: PMC10142927
Review Free full text in Europe PMC
Go to all (235) article citations
Other citations
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents.
Prog Neurobiol, 82(6):348-360, 19 Jun 2007
Cited by: 85 articles | PMID: 17659826
Review
Alzheimer's disease: treatments in discovery and development.
Nat Neurosci, 5 Suppl:1055-1057, 01 Nov 2002
Cited by: 87 articles | PMID: 12403985
Review
[Therapy of Alzheimer disease].
Neuropsychopharmacol Hung, 11(1):27-33, 01 Mar 2009
Cited by: 13 articles | PMID: 19731816
Review
Alzheimer's disease: from pathology to therapeutic approaches.
Angew Chem Int Ed Engl, 48(17):3030-3059, 01 Jan 2009
Cited by: 226 articles | PMID: 19330877
Review